BNP Paribas Financial Markets Increases Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

BNP Paribas Financial Markets boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 23.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 413,409 shares of the biopharmaceutical company's stock after purchasing an additional 78,824 shares during the period. BNP Paribas Financial Markets owned 0.32% of Dynavax Technologies worth $5,779,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. E Fund Management Co. Ltd. increased its stake in shares of Dynavax Technologies by 18.5% during the 4th quarter. E Fund Management Co. Ltd. now owns 29,016 shares of the biopharmaceutical company's stock worth $406,000 after purchasing an additional 4,532 shares during the last quarter. Natixis Advisors L.P. lifted its position in shares of Dynavax Technologies by 10.5% in the fourth quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company's stock worth $266,000 after buying an additional 1,804 shares during the last quarter. SummerHaven Investment Management LLC boosted its stake in shares of Dynavax Technologies by 1.5% during the 4th quarter. SummerHaven Investment Management LLC now owns 52,973 shares of the biopharmaceutical company's stock worth $741,000 after acquiring an additional 799 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of Dynavax Technologies by 5.7% during the 4th quarter. New York State Common Retirement Fund now owns 52,725 shares of the biopharmaceutical company's stock worth $737,000 after acquiring an additional 2,860 shares in the last quarter. Finally, Illinois Municipal Retirement Fund increased its holdings in shares of Dynavax Technologies by 8.9% during the 4th quarter. Illinois Municipal Retirement Fund now owns 77,139 shares of the biopharmaceutical company's stock valued at $1,078,000 after acquiring an additional 6,333 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.

Wall Street Analysts Forecast Growth

DVAX has been the subject of a number of recent analyst reports. StockNews.com cut Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Friday, April 26th. The Goldman Sachs Group began coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They issued a "neutral" rating and a $20.00 target price on the stock. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research note on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $25.33.

Insiders Place Their Bets

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.98% of the company's stock.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX traded up $0.28 on Monday, hitting $11.39. 1,710,240 shares of the company were exchanged, compared to its average volume of 2,056,398. The company's 50 day moving average price is $11.81 and its two-hundred day moving average price is $12.86. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 189.83 and a beta of 1.30. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.10 and a current ratio of 15.20. Dynavax Technologies Co. has a one year low of $10.48 and a one year high of $15.15.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.